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To investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of D-galactosamine (GalN),
we focused on the role of polyprimidine tract-binding protein (PTB) in islet insulin synthesis. Recent reports indicate that PTB binds and
stabilizes mRNA encoding insulin and insulin secretory granule proteins, including islet cell autoantigen 512 (ICA512), prohormone convertase
1/3 (PC1/3), and PC2. In the present study, glucose-stimulated insulin secretion was significantly increased in GalN-treated rats compared to
controls. Levels of mRNA encoding insulin 1, ICA512, and PC1/3 were increased in the pancreatic islets of GalN-treated rats. This mRNA level
elevation was not prevented by pretreatment with actinomycin D. When the PTB-binding site in insulin 1 mRNA was incubated with the islet
cytosolic fraction, the RNA–protein complex level was increased in the cytosolic fraction obtained from GalN-treated rats compared to the level
in control rats. The cytosolic fraction obtained from pancreatic islets obtained from GalN-treated rats had an increased PTB level compared to
the levels obtained from the pancreatic islets of control rats. These findings suggest that, in rats with acute liver failure, cytosolic PTB binds and
stabilizes mRNA encoding insulin and its secretory granule proteins.
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It has long been recognized that liver cirrhosis is associated
with impaired glucose metabolism. Patients with liver cirrhosis
commonly have increased fasting and glucose-induced insulin
levels [1–6]. Studies indicate that hyperinsulinaemia in cirrhotic
patients is related to increased pancreatic insulin secretion [2–6]
and to decreased hepatic insulin extraction [1,2,4]. However,
several studies suggest that, in cirrhotic patients, reduced
hepatic extraction of insulin only occurs in the advanced stages
of the disease [3,6]. Patients with acute liver failure (ALF) also
exhibit severe alterations of glucose metabolism, including
insulin resistance [7–11] and increased pancreatic insulin
secretion [8–11]. Improving the hyperinsulinaemia of patients⁎ Corresponding author. Fax: +81 88 633 7082.
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doi:10.1016/j.bbadis.2006.10.001with ALF may help prolong their survival and shorten their
recovery period. Furthermore, studies of patients with ALF
suggest that insulin biosynthesis is activated in the early stage of
liver disease [8–11]. In addition, in an animal ALF model, islet
insulin content and biosynthesis were found to be significantly
increased [12]. However, the mechanisms related to this
increase in insulin biosynthesis associated with ALF have not
yet been established.
Glucose is the main regulator of insulin biosynthesis [13].
Recent findings indicate that glucose promotes the rapid
nucleocytoplasmic translocation of polypyrimidine tract-bind-
ing protein (PTB) in rat pancreatic islets and insulinoma INS-1
cells [14]. Cytosolic PTB binds and stabilizes both mRNA
encoding insulin [15] and insulin secretory granule proteins,
including islet cell autoantigen 512 (ICA512), prohormone
convertase 1/3 (PC1/3), and PC2 [14], which promotes their
translation. These findings suggest that PTB is a key factor that
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secretion. In the present study, we investigated the roles that
PTB plays in regulating the expression of the genes encoding
insulin and its secretory granule proteins in ALF.
2. Materials and methods
2.1. Animals and experimental design
The animal facilities and protocol were reviewed and approved by the
Institutional Animal Care and Use Committee of Tokushima University. Male
Sprague–Dawley rats (weight, about 200 g) were housed under a 12-h light/
dark cycle, and had free access to a commercially available diet and water. After
the rats were deprived of food for 12 h, one group (GalN-treated rats) was
injected intraperitoneally with D-galactosamine (GalN, Sigma, St. Louis, MO)
dissolved in phosphate-buffered saline (PBS) at a single dose of 400 mg/kg
body weight. The control rats were injected with PBS. Some of the GalN-
treated rats were given an intraperitoneal injection of actinomycin D (Sigma) at
a dose of 750 μg/kg body weight 1 h before the GalN injection. Twelve hours
after the GalN (or PBS) injection, the rats were anesthetized by an intraperitoneal
injection of pentobarbital, and pancreatic islets were isolated by collagenase
digestion of the pancreas according to the method of Gotoh et al. [16]. Briefly,
after the distal end of the bile duct was clamped, 12 mL of collagenase solution
(typeXI, Sigma, 0.32 mg/mL) were injected into the common bile duct. The
distended pancreas was excised and transferred into a 50-mL plastic tube. After
incubation for 40 min at 37 °C, cold Hanks' balanced salt solution (HBSS) was
added. The plastic tube was gently vortexed and then centrifuged. The pellet was
washed gently three times with cold HBSS. Next, the tissue suspension was
passed through a mesh filter to remove large undigested tissue. The filtered
tissue was then washed again and the pellet was resuspended in 4 mL of a 25%
Ficoll solution (GE Healthcare, Piscataway, NJ). The tissue suspension was
overlaid with a discontinuous Ficoll gradient (23%, 20.5%, and 11%, 2 mL of
each), and this was followed by centrifugation at 800×g for 10 min. The tissue
at the 20.5/11 interface was collected and washed with HBSS. The isolated
islets were immediately used for sample extraction.
2.2. Measurement of plasma alanine aminotransferase (ALT), glucose,
and insulin
The plasma ALTconcentration was measured by the LDH-UVmethod using
an autoanalyzer. The plasma concentration of glucose and insulin were
measured using the Glucose-CII test (Wako, Osaka, Japan) and ELISA Insulin
Kit (Morinaga, Yokohama, Japan), respectively.
2.3. Oral glucose tolerance test
Twelve hours after the GalN (or PBS) injection, some of the rats were given
a 20% (W/V) glucose solution at a dose of 2 g/kg body weight by oral gavage.Table 1
Sequences of primers used for real-time RT-PCR
Insulin 1 (J00747) Sense
Antisense
ICA512 (NM_053881) Sense
Antisense
PC1/3 (NM_017091) Sense
Antisense
CPE (M31602) Sense
Antisense
β-actin (BC063166) Sense
Antisense
18S rRNA (M11188) Sense
Antisense
The GenBank accession numbers are indicated in brackets. The primer sequences aAt 0, 30, 60, and 120 min after this glucose loading, blood was drawn from the
tail vein and used for plasma glucose and insulin assays.
2.4. Quantitative real-time RT-PCR
Total RNA was extracted from pancreatic islets using the ISOGEN
system (Nippon Gene, Tokyo, Japan) according to the manufacturer's
protocol. The first-strand cDNA was synthesized using a first-strand
synthesis kit (Invitrogen Corp., Carlsbad, CA). Real-time RT-PCR (Light-
Cycler, Roche Diagnostics, Indianapolis, IN) was done using a QuantiTect
SYBR Green PCR kit (Qiagen, Valencia, CA). Each sample was analyzed
in triplicate. The specific primers used for real-time RT-PCR are shown in
Table 1. The mRNA levels were normalized to the level of 18S ribosomal
RNA (rRNA).
2.5. Preparation of cell extracts
Cell extracts were prepared using the method described by Andrews
et al. [17]. Islets prepared from 3 individual rats in the same group were
pooled and suspended in 100 μl of cold buffer A (10 mM HEPES–KOH
(pH 7.9), 1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol, and
0.2 mM phenylmethylsulfonyl fluoride). The cells were allowed to swell on
ice for 10 min, and then vortexed for 10 s. Samples were centrifuged for
10 s, and then the pellet was resuspended in PBS (nuclear fraction). The
supernatant fraction was recentrifuged at 13,000×g for 10 min at 4 °C.
This supernatant fraction was used as the cytosolic fraction. Protein
concentration was analyzed using the BCA protein assay reagent (Pierce,
Rockford, IL).
2.6. RNA mobility shift analysis
The construction of the insulin 1 cRNA expression vector and the
preparation of the cRNA probe were done as previously described [18].
The RNA probe (10,000 cpm) was denatured at 70 °C for 10 min and
then gradually cooled to room temperature. The binding reaction was
performed with the cytosolic fraction and the RNA probe placed in a
binding buffer containing 10 mM HEPES (pH 7.9), 5 mM MgCl2,
50 mM KCl, 1 mM dithiothreitol and 10% glycerol at 30 °C for 30 min.
Following digestion with 5 units of RNase T1 (Roche Diagnostics), the
samples were separated by 5% PAGE. The dried gel was analyzed using
a Fuji BAS-1500 system.
2.7. Western blot analysis
Western blot analysis was carried out as described previously [19].
After blocking, the membranes were incubated with anti-PTB antibody
(Zymed Laboratories Inc., CA) or anti-tubulin antibody (Sigma) overnight
at 4 °C.Sequence Position
ACAGCACCTTTGTGGTCC 4262–4579
GGACTCAGTTGCAGTAGTTC 4518–4499
TGCGCTCATTGCTGCTTACTCTG 1733–1755
GGCGCTCCTTATCCCGTTGTTT 1846–1825
GTACCCAAAAACTCCAGCAG 2143–2162
GGCTTGTTGAGCTTTTCCAG 2345–2326
TTGGGAACATGCATGGTAATGAG 388–410
CACGAACCAGTCCTTCAGCTC 590–570
GCCCTGGCTCCTAGCACC 1036–1053
CCACCAATCCACACAGAGTACTTG 1109–1086
AGTCCCTGCCCTTTGTACACA 1691–1711
GATCCGAGGGCCTCACTAAAC 1758–1738
re written from 5′ to 3′ end.
Table 2
Body weight, liver weight, plasma ALT, plasma glucose, and plasma insulin of
controls and GalN-treated rats
Controls GalN-treated rats
Body weight (g) 191±4 199±5
Liver weight (g) 6.0±0.2 6.7±0.2 a
Plasma ALT (U/L) 21±3 123±16a
Plasma glucose (mg/dl) 93.5±8.5 95.2±7.2
Plasma insulin (pg/ml) 520.3±32.5 533.7±58.2
Results are expressed as mean±SE, n=7.
a Significantly different from control group, P<0.05.
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Data are expressed as mean±SE. To assess the significance of the
differences between 2 experimental groups, we performed ANOVA followed
by Student's t-test. A probability level of P<0.05 was considered to indicate
significance.
3. Results
3.1. Body and liver weight, plasma ALT, glucose, and insulin
levels in GalN-treated rats
The rats injected with GalN developed ALF, reflected by the
increase in their plasma ALT activity after the injection
compared to controls (Table 2). The liver weight of GalN-
treated rats was significantly greater than that of control rats,
although there was no significant difference in body weight
between the 2 groups (Table 2).
There was no significant difference in fasting plasma
glucose or in insulin concentrations between the GalN-treatedFig. 1. Plasma glucose and insulin response after oral glucose loading in GalN-
treated rats. Twelve hours after GalN or vehicle injection, the rats were given
glucose at a dose of 2 g/kg body weight. Plasma glucose (A) and insulin (B)
concentration were measured 0, 30, 60, and 120 min after glucose loading.
Values are mean±SE; n=3. *Significantly different from control (P<0.05).rats and control rats (Table 2). The 2 groups exhibited similar
changes in plasma glucose concentration after oral glucose
loading (Fig. 1A). However, 30 min after oral glucose loading,
the GalN-treated rats had a significantly higher plasma insulin
concentration than controls (Fig. 1B).
3.2. Levels of mRNAs encoding insulin 1 and insulin secretory
granule proteins in the islets from the pancreas of GalN-treated
rats
The GalN-treated rats had significantly increased pancreatic
islet levels of the mRNAs encoding insulin 1, ICA512, PC1/3,
and carboxypeptidase E (CPE) by 160%, 202%, 198%, and
155%, respectively, compared with the corresponding pan-
creatic islet levels in controls (Fig. 2A). There was no significant
difference in the level of islet β-actin mRNA levels between the
2 groups (Fig. 2A). In these experiments, each PCR product was
detected in a single band that migrated to the expected size
(Fig. 2B).
To investigate whether transcriptional or posttranscriptional
mechanisms mediate changes in the expression of mRNAs
encoding insulin and its secretory granule proteins, some of the
GalN-treated rats were given an intraperitoneal injection of
actinomycin D (Sigma), which inhibits transcription, before the
GalN injection. Treatment with actinomycin D but without the
GalN injection decreased the islet β-actin mRNA level by 56%
compared to the islet levels in normal rats that had neither
actinomycin D nor GalN treatment (data not shown). On theFig. 2. Levels of mRNAs encoding insulin 1 and insulin secretory granule
proteins in the pancreatic islets of GalN-treated rats. (A) The levels of mRNAs
encoding insulin 1, ICA512, PC1/3, CPE, and β-actin in the islets were
measured using real-time RT-PCR. The mRNA levels were normalized to the
level of 18S rRNA. Values are mean±SE; n=9. *Significantly different from
control group (P<0.05). (B) PCR products were separated by electrophoresis
using 1.8% agarose gel and stained with ethidium bromide.
Fig. 3. Effect of actinomycin D on levels of mRNAs encoding insulin 1 and
insulin secretory granule proteins in the pancreatic islets of GalN-treated rats.
Starved rats were injected with actinomycin D 1 h before the GalN injection. The
levels of mRNAs encoding insulin 1, ICA512, PC1/3, CPE, and β-actin in the
pancreatic islets were measured using real-time RT-PCR. The mRNA levels
were normalized to the level of 18S rRNA. Values are mean±SE; n=6.
*Significantly different from control group (P<0.05).
Fig. 5. Western blot analysis of PTB. Preparation of islet cell extracts was done
as described inMaterials and methods. Both nuclear and cytosolic fractions were
analyzed by Western blotting using anti-PTB and anti-tubulin antibodies. C,
controls; G, GalN-treated rats. The results shown are representative of three
independent experiments.
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injection significantly increased islet levels of mRNAs encod-
ing insulin 1, ICA512, and PC1/3 by 140%, 151%, and 162%,
respectively, compared with the corresponding islet levels in
controls (Fig. 3). However, pretreatment with actinomycin D
abolished the GalN-induced increase in the islet CPE mRNA
levels (Fig. 3).
3.3. Binding activity of the cytosolic fraction to the
3′-untranslated region (UTR) of insulin 1 mRNA
The insulin 1 mRNA 3′-UTR contains an evolutionary
conserved consensus binding site for PTB [15]. To determineFig. 4. RNA mobility shift analysis using the PTB binding sequence of insulin 1
mRNA. The cytosolic fraction was prepared as described in the Materials and
methods section. The RNA probe was incubated alone (lane 1) or with 3 μg
(lanes 2–5) of cytosolic fraction prepared from pooled islets of controls
(lanes 2,3) or GalN-treated rats (lanes 4,5). The reaction products were separated
by 5% PAGE. The data shown are the results from 2 individual extracts from
each group; these extracts were prepared in independent experiments.whether GalN treatment promotes the binding of PTB to its 3′-
UTR, gel mobility shift analysis was performed. The putative
PTB-binding site in rat insulin 1 mRNA was incubated with
cytosolic fractions prepared from the islets of control and GalN-
treated rats. The insulin mRNA–protein complex level was
increased in the cytosolic fraction obtained from GalN-treated
rats (Fig. 4, lanes 4,5), compared to the level in the cytosolic
fraction of controls (Fig. 4, lanes 2,3).
3.4. Localization of PTB protein in the islets of GalN-treated
rats
Translocation of PTB from the nucleus to the cytosol has
previously been observed in glucose-stimulated islet cells [14].
To determine whether GalN treatment induces PTB accumula-
tion in the cytosolic fraction, Western blot analysis was
performed (Fig. 5). In the pancreatic islets of controls, PTB
was mainly found in the nuclear fraction. However, the
pancreatic islets of GalN-treated rats had a significantly
increased level of PTB in the cytosolic fraction, compared to
the pancreatic islets of controls. Thus, in addition to the
translocation of the 59 kDa PTB isoform, GalN treatment
enhanced the levels of a 27 kDa PTB species in the nuclear
fraction of the islets.
4. Discussion
Hyperinsulinaemia is a well-known feature of liver failure
[1–6,8–11]. In cirrhotic patients with hepatocellular carcinoma,
hyperinsulinaemia after oral glucose intake is a significant
factor that contributes to the growth rate of hepatocellular
carcinoma [20]. In insulin-resistant cirrhotic patients, improving
their hyperinsulinaemia can normalize their reduced insulin
sensitivity [21]. Furthermore, metabolic states in cirrhotic
patients are quite similar to those observed in healthy subjects
after 2 to 3 days of starvation [22]. Therefore, hyperinsulinae-
mia may lead to hypoglycemia in cirrhotic patients. Treatment
of hyperinsulinaemia in patients with liver failure may have a
beneficial effect.
In pancreatic β-cells, proinsulin is synthesized and processed
into its biologically active form, insulin [23]. Insulin is stored
within mature secretory granules, which are secreted in
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the liver is the primary site of insulin clearance [25]. The
mechanisms of hyperinsulinaemia in chronic liver disease
include decreased insulin removal by the cirrhotic liver [4,26],
and escape of insulin from liver degradation because of portal
systemic shunting [27,28]. In the present study, hepatic
extraction of insulin may have been preserved in GalN-treated
rats, since fasting insulin levels did not increase, and
hyperinsulinaemia was detected only 30 min after the oral
glucose load.
Recent findings suggest that secretory granule proteins and
prohormone convertases play important roles in the regulation
of β-cell insulin content and secretion in response to stimuli
[29,30]. Overexpression of ICA512 in MIN-6 cells, a mouse
pancreatic β-cell line, resulted in an increase in the number of
secretory granules and the insulin content in those cells [29].
When stimulated with glucose or K+, ICA512-overexpressing
MIN-6 cells have been found to secrete much more insulin than
control MIN-6 cells [29]. On the other hand, PC1/3-null β-cells
have been found to contain very high levels of stored
proinsulin-related material and a large number of immature-
appearing secretory granules [30]. A previous study indicated
that pancreatic islets of GalN-treated rats had a significantly
increased insulin content [12]. In the present study, the levels of
the mRNAs encoding insulin and its secretory granule proteins
were increased in the pancreatic islets of GalN-treated rats. This
finding partly explains the increased insulin content found in
GalN-treated rat islets.
The 3′-UTR of mRNAs encoding insulin 1, ICA512, and
PC1/3, but not CPE, contains the consensus binding site for
PTB [14,15]. The binding of cytosolic PTB to these mRNAs
leads to their stabilization and increased translation [14,15]. In
the present study's gel mobility shift analysis using the PTB-
binding site in insulin 1 mRNA, we showed that the cytosolic
extract of pancreatic islets of GalN-treated rats had an increased
level of RNA–protein complex, compared to the level in
controls. The mechanism of insulin 1 mRNA stabilization in the
pancreas of GalN-treated rats may involve PTB binding. In a
future study, it will be important to determine whether this
insulin mRNA–protein complex truly contains PTB and
whether the binding of PTB to mRNAs encoding ICA512 and
PC1/3 is affected by GalN treatment.
In the present study, we demonstrated that GalN treatment
promotes the nucleocytoplasmic translocation of PTB in islets.
Furthermore, there were increased levels of a 27 kDa PTB
species that probably represents a carboxy-terminal proteolytic
fragment of a 59 kDa form [31] in the nuclear fraction of
pancreatic islets obtained from GalN-treated rats. This expres-
sion pattern coincides with that of islets stimulated by glucose
[14]. A recent study suggests that cAMP-dependent phosphor-
ylation of PTB by protein kinase A induces its nucleocyto-
plasmic transport in neuroendocrine PC12 cells [32] and in INS-
1 cells [33]. However, phosphorylation of PTB in INS-1 cells
stimulated by glucose has not been detected, although
translocation of PTB from the nucleus to the cytosol has been
observed [33]. In addition to protein kinase A-dependent
phosphorylation, other mechanisms may also elicit the trans-location of PTB in INS-1 cells stimulated by glucose. To clarify
the mechanisms that regulate PTB translocation in pancreatic
islets of GalN-treated rats, it will be important to study
phosphorylation state of PTB.
Several transcription factors play important roles in the
maintenance of β-cell function [34]. In the present study,
GalN-treated rats had a significantly increased islet CPE
mRNA level. This reflects transcriptional regulation, since
pretreatment with actinomycin D abolished the CPE mRNA
level increase in the pancreatic islets of GalN-treated rats. CPE
is also an important molecule that regulates insulin effects;
CPE missense polymorphisms have been found in patients
with type 2 diabetes mellitus [35]. Furthermore, the plasma
proinsulin level in CPE knockout mice was 50–100 times
higher than in wild type mice [36]; as well, CPE over-
expression increases insulin secretion and proinsulin proces-
sing in rat pituitary GH3 cell clones engineered to secrete
human insulin [37]. In the future, it will be important to clarify
the transcriptional regulation of the CPE gene in the so as to
understand the molecular mechanisms of hyperinsulinaemia in
GalN-treated rats.
The present findings indicate that the increased levels of
mRNAs encoding insulin and its secretory granule proteins in
the pancreatic islets of rats with ALF are the result of
transcriptional and posttranscriptional events. Posttranscrip-
tional regulation may be induced by the binding of PTB to the
PTB-binding sequence in these mRNAs. These findings appear
to at least partly explain the increased insulin secretion in
patients with liver failure.
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